The Pharmaceutical Research and Manufacturers of America released the first industrywide principles on clinical trial diversity, shortly after the FDA released its final guidance on clinical trial diversity.
PhRMA's principles focus on four main areas:
- Building trust and acknowledging the historic mistrust of clinical trials within Black and brown communities
- Reducing barriers to clinical trial access
- Using real-world data to enhance information on diverse populations beyond product approval
- Enhancing information about diversity and inclusion in clinical trial participation
All of PhRMA's member companies can voluntarily adopt the principles. PhRMA is the drug industry's top lobbying group and represents some of the country's biggest drugmakers, including Eli Lilly, AbbVie and AstraZeneca.
"The industry’s new clinical trial diversity principles are an important step toward greater health equity. We are addressing issues of mistrust and working to reduce systemic issues that deter communities of color from participating in clinical trials, so that those patients who want to participate, can," said Stephen Ubl, president and CEO of PhRMA.
Read the full news release here.